1. Home
  2. AON vs NTRA Comparison

AON vs NTRA Comparison

Compare AON & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aon plc (Ireland)

AON

Aon plc (Ireland)

HOLD

Current Price

$344.71

Market Cap

57.2B

Sector

Finance

ML Signal

HOLD

Logo Natera Inc.

NTRA

Natera Inc.

SELL

Current Price

$390.91

Market Cap

56.7B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
AON
NTRA
Founded
1919
2003
Country
Ireland
United States
Employees
N/A
N/A
Industry
Specialty Insurers
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
57.2B
56.7B
IPO Year
1995
2015

Fundamental Metrics

Financial Performance
Metric
AON
NTRA
Price
$344.71
$390.91
Analyst Decision
Buy
Strong Buy
Analyst Count
21
23
Target Price
$363.21
★ $416.39
AVG Volume (30 Days)
★ 1.6M
1.5M
Earning Date
10-28-2026
11-05-2026
Dividend Yield
★ 0.99%
N/A
EPS Growth
★ 36.27
0.65
EPS
★ 10.46
N/A
Revenue
★ $10,770,000,000.00
$210,939,000.00
Revenue This Year
$4.33
$26.20
Revenue Next Year
$20.86
$20.89
P/E Ratio
$31.45
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$266.33
$181.00
52 Week High
$382.34
$437.41

Technical Indicators

Market Signals
Indicator
AON
NTRA
Relative Strength Index (RSI) 71.02 46.14
Support Level $310.26 $382.08
Resistance Level $334.63 $437.41
Average True Range (ATR) 7.68 19.70
MACD 5.43 -3.99
Stochastic Oscillator 92.03 17.90

Price Performance

Historical Comparison
AON
NTRA

About AON Aon plc (Ireland)

Aon is a leading global provider of insurance and reinsurance brokerage and human resources solutions. Its operations are tilted toward its brokerage operations. Headquartered in London, Aon has about 60,000 employees and operations in over 120 countries.

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Share on Social Networks: